6VWC

Crystal structure of Bcl-xL in complex with tetrahydroisoquinoline-pyridine based inhibitors


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.60 Å
  • R-Value Free: 0.200 
  • R-Value Work: 0.179 
  • R-Value Observed: 0.180 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X L Inhibitor.

Wang, L.Doherty, G.A.Judd, A.S.Tao, Z.F.Hansen, T.M.Frey, R.R.Song, X.Bruncko, M.Kunzer, A.R.Wang, X.Wendt, M.D.Flygare, J.A.Catron, N.D.Judge, R.A.Park, C.H.Shekhar, S.Phillips, D.C.Nimmer, P.Smith, M.L.Tahir, S.K.Xiao, Y.Xue, J.Zhang, H.Le, P.N.Mitten, M.J.Boghaert, E.R.Gao, W.Kovar, P.Choo, E.F.Diaz, D.Fairbrother, W.J.Elmore, S.W.Sampath, D.Leverson, J.D.Souers, A.J.

(2020) ACS Med Chem Lett 11: 1829-1836

  • DOI: 10.1021/acsmedchemlett.9b00568
  • Primary Citation of Related Structures:  
    6VWC

  • PubMed Abstract: 
  • Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-X L inhibitor that selectively and potently induces apoptosis in BCL-X L -dependent tumor cells. This molecule was generated by re-engineering our previously reported BCL-X L inhibitor A-1155463 using structure-based drug design ...

    Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-X L inhibitor that selectively and potently induces apoptosis in BCL-X L -dependent tumor cells. This molecule was generated by re-engineering our previously reported BCL-X L inhibitor A-1155463 using structure-based drug design. Key design elements included rigidification of the A-1155463 pharmacophore and introduction of sp 3 -rich moieties capable of generating highly productive interactions within the key P4 pocket of BCL-X L . A-1331852 has since been used as a critical tool molecule for further exploring BCL-2 family protein biology, while also representing an attractive entry into a drug discovery program.


    Organizational Affiliation

    AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Bcl-2-like protein 1A, B167Homo sapiensMutation(s): 3 
Gene Names: BCL2L1BCL2LBCLX
UniProt & NIH Common Fund Data Resources
Find proteins for Q07817 (Homo sapiens)
Explore Q07817 
Go to UniProtKB:  Q07817
PHAROS:  Q07817
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
RQ7 (Subject of Investigation/LOI)
Query on RQ7

Download Ideal Coordinates CCD File 
C [auth A], D [auth B]6-{8-[(1,3-benzothiazol-2-yl)carbamoyl]-3,4-dihydroisoquinolin-2(1H)-yl}-3-{1-[(pyridin-4-yl)methyl]-1H-pyrazol-4-yl}pyridine-2-carboxylic acid
C32 H25 N7 O3 S
WBCFKELVKOCTOB-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.60 Å
  • R-Value Free: 0.200 
  • R-Value Work: 0.179 
  • R-Value Observed: 0.180 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 33.304α = 90
b = 94.584β = 90.93
c = 54.272γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
XSCALEdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2020-10-21
    Type: Initial release
  • Version 1.1: 2020-11-04
    Changes: Database references